Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-528-5 | CAS number: 29232-93-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Experimental start: October 1979, experimental end: February 1980
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
- Report date:
- 1980
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-2 (Repeated Dose Dermal Toxicity -21/28 Days)
- Version / remarks:
- August 1978
- Deviations:
- no
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Pirimiphos-methyl
- EC Number:
- 249-528-5
- EC Name:
- Pirimiphos-methyl
- Cas Number:
- 29232-93-7
- Molecular formula:
- C11H20N3O3PS
- IUPAC Name:
- O-2-(diethylamino)-6-methylpyrimidin-4-yl O,O-dimethyl phosphorothioate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Details on species / strain selection:
- This strain is the species recommended in the EPA test guideline. The strain was selected because it is readily available, is easy to handle, house, dose and bleed. There is a considerable amount of published toxicological information available on this species to assist in the assessment of the significance to man of any chemically induced changes.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Supplier: Ranch Rabbits, Crawley Down, Sussex, England
Age: not specified
Weight: 2.25 to 2.9 kg (males), 2.18 to 2.9 kg (females); weights in additional control group were 2.86 to 3.0 kg (males), 2.95 to 3.17 kg (females)
Acclimatisation: 12 days
Housing: individually in grid floor cages in a single room with fan controlled air circulation
Temperature: 13 to 21 °C
Humidity: 30 to 80%
Lightning: photoperiod of 14 hours light to 10 hours darkness
Diet: Ranch Pellets, Grain Harvesters Ltd, Wingham, Canterbury, Kent ad libitum
Water: filtered mains tap water ad libitum
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- propylene glycol
- Details on exposure:
- The back and flanks of each animal were clipped free of hair using veterinary clippers 24 hours prior to first administrations. The treatment area was about 10% of the total body surface. It was reclipped at intervals to avoid that the regrowth of hair would have an effect on contact between test substance and skin. In additional groups, the treatment area was abraded once every seven days using a clipper head. The abrasion penetrated the horny layer of the epidermis but did not cause bleeding or damage to the underlying dermis.
Daily doses of the test substance or control substance were applied to the intact or abraded skin areas based on individual body weights.
A gauze pad (10 cm x 10 cm) was placed over the treated area and secured with a strip of impermeable adhesive plaster. This was held in place by a canvas jacket which was wrapped securely around the trunk of the animal. An Elizabethan collar was placed around the neck of each animal to prevent oral ingestion and interference with the wrappings. About six hours after the treatment the plasters and gauze were removed and the skin sites wiped to remove any test substance still remaining. - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Not applicable
- Duration of treatment / exposure:
- 3 weeks
- Frequency of treatment:
- Five days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 4 mg/kg bw/day (nominal)
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 400 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- Five females, five males
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Animals were allocated to treatment groups by means of a randomisation procedure based on body weight.
- Positive control:
- Not applicable
Examinations
- Observations and examinations performed and frequency:
- Appearance, behaviour, general: all animals were observed at least once daily for overt signs of toxicity or behavioural change
Skin irritation: skin reactions were evaluated daily immediately prior to the application of the substance (erythema, oedema, desquamation not including eschar area, fissuring, atonia not including eschar area, eschar formation, exfoliation, folding)
Body weight: individual weights were recorded on the start of the study, then twice weekly and on the day of sacrifice
Food consumption: the total amount of food consumed per day was recorded daily
Haematology: a sample of blood (approximately 0.5 mL) was extracted from the marginal ear vein to perform haematological investigations
Clinical chemistry: a sample of blood (approximately 2 mL) was extracted from the marginal ear vein to perform analysis of blood clinical chemistry - Sacrifice and pathology:
- The brain was divided into two equal portions at necropsy, and one side was processed for microscopic examination. The other side was homogenised to examine the cholinesterase activity.
Necropsies were carried out on all animals, which were painlessly killed by intravenous overdose of pentobarbitone sodium chloride. Major tissues and organs were examined for the presence of gross lesions. Organs were weighed prior to fixation (adrenals, brain, heart, kidneys, liver, ovaries, pituitary, testes, thyroids). A number of tissues and organs were fixed in 10% neutral buffered formalin (adrenals, brain, heart, kidneys, liver, ovaries, pituitary, testes, thyroids, treated skin, untreated skin, all unusual lesions). Samples of the tissues and organs were set in paraffin wax blocks, sectioned at a nominal thickness of 5 µm and stained with haematoxylin and eosin for microscopic examination. - Statistics:
- Data were processed where possible to give dose and sex group mean values and standard deviations. Raw and processed data were examined for evidence of any toxicologically significant effects resulting from treatment. The study pathologist interpreted the macroscopic and microscopic pathology findings.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical signs periodically observed included lethargy, swelling of the abdomen, emaciation, enteric discharge, perianal staining and nasal and ocular discharges.
- Dermal irritation:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Skin irritation was observed in animals of all treatment groups. Animals treated at 400 mg/kg bw/day commonly showed moderate erythema, slight to moderate oedema and atonia and slight desquamation. Severe erythema and moderate desquamation were noted in some animals, but these observations were infrequent. In general, erythema was recorded throughout the study, oedema and atonia were recorded during weeks 2 and 3 and desquamation was recorded during week 3 only. Similar skin reactions were recorded within the high dose group for female and male animals and for animals with intact and abraded skin.
Skin reactions commonly described for animals treated at 40 and 4 mg/kg bw/day were slight erythema, atonia or desquamation. Animals treated at 40 mg/kg bw/day also occasionally showed slight oedema and moderate erythema (throughout the study), atonia or desquamation (during week 3 only). The skin reactions were similar for female and male animals and for animals with intact or abraded skin. Control animals showed slight erythema and desquamation periodically during the study. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Three animals in the group treated at 400 mg/kg bw/day, and one animal each in the groups treated at 40 and 4 mg/kg bw/day died early during the study. The deaths of the five animals were not considered related to treatment, but to respiratory and enteric disturbances associated with common laboratory diseases.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight changes of animals treated with the substance were, in general, similar to those of control animals throughout the study. However, females in the group of animals with abraded skin treated at 400 mg/kg bw/day had no body weight gains at all records after day 8 of the study compared to control animals or those in the other treatment groups.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The recordings of the food consumption indicated an equivocal effect of treatment on the consumption of food by male and female animals with abraded skin treated at 400 mg/kg bw/day. These animals consumed in general less food than the corresponding control animals or those in the other treatment groups.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The erythrocyte and plasma activity of acetyl cholinesterase was depressed in blood samples taken from the animals treated at 400 mg/kg bw/day after 17 or 18 days of treatment. The pre-dose levels of the enzyme in this group were similar to both the pre-dose and terminal levels of the control groups or the other treatment groups being in the range of 147 to 265 iu/L (erythrocyte) and 291 to 413 iu/L (plasma). The terminal levels in the group treated at 400 mg/kg bw/day were noticeably lower in the range of 59 to 113 iu/L (erythrocyte) and 146 to 224 iu/L (plasma). No other dose-related changes occurred in any of the other clinical chemistry parameters examined. No significant effects on the activity of cholinesterase in the brain could be seen.
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Propylene glycol (used as vehicle) produced minor skin reactions consisting of minimal to slight hyperkeratosis, acanthosis and hypergranulosis in the epidermis and a low grade of inflammatory reaction in the superficial dermis. The reactions to the test substance were of a similar type but slightly more extensive. The overall epidermal score for the three main parameters assessed was increasing in a dose-related manner. However, even at the highest dermal dose the epidermis was intact and showed only slight to moderate acanthosis, and the dermal inflammatory reaction was of a generally low grade.
Five animals died early in the study. Two of the three deaths in the group treated at 400 mg/kg bw/day were associated with poor respiratory conditions, but the cause of one death was not established. The two incidental deaths in the groups treated at 40 and 4 mg/kg bw/day were probably associated with enteric conditions.
Necropsy and histopathology findings in the surviving rabbits were generally infrequent and of a minor nature such as lymphoid or leucocyte foci in the liver and ectopic thymic tissue associated with the thyroid glands. There were no findings of any type or incidence to suggest any systemic, toxic effects related to the treatment with the substance. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Necropsy and histopathology findings in the surviving rabbits were generally infrequent and of a minor nature such as lymphoid or leucocyte foci in the liver and ectopic thymic tissue associated with the thyroid glands. There were no findings of any type or incidence to suggest any systemic, toxic effects related to the treatment with the substance.
- Histopathological findings: neoplastic:
- not examined
Applicant's summary and conclusion
- Conclusions:
- The NOAEL for systemic toxicity in a 21-day dermal repeated dose toxicity study was 40 mg/kg bw/day.
- Executive summary:
The repeated dose toxicity of the substance following application to the skin of healthy male and female New Zealand White rabbits was studied in accordance with EPA Test Guideline 82-2. Three groups of 10 rabbits (5 per sex) with intact skin and three groups of 10 rabbits (5 per sex) with abraded skin were treated with the substance suspended in propylene glycol at doses of 4, 40 and 400 mg/kg bw/day. The substance was applied under occlusion (gauze pad fixed with impermeable plasters and held in place by a canvas jacket) for six hours per day on five days per week for a total period of three weeks. An Elizabethan collar was placed around the neck of each animal to prevent oral ingestion or interference with the wrappings. Following the six hour exposure period, the plasters and gauze were removed and the skin sites wiped to remove any remaining test substance.
Three animals in the group treated at 400 mg/kg bw/day, one animal in the group treated at 40 mg/kg bw/day and one animal in the group treated at 4 mg/kg bw/day died during the study. The deaths mostly occurred in the early phase of the study (between days 2 and 5) and were probably caused by spontaneous disease (e.g. poor respiratory or enteric conditions). However, the cause of the death of one animal on study day 11 could not be established. No adverse treatment-related clinical signs were noted during the study. Clinical signs indicative of common laboratory disease syndromes were observed in animals of all groups. Skin irritation consisting of erythema, oedema, desquamation and atonia was observed in animals of all treatment groups. These reactions were, in general, slight to moderate in animals treated at 400 mg/kg bw/day and slight in animals treated at lower levels. The body weight increases of some animals treated at 400 mg/kg bw/day were lower than those of control animals during the second and third week of the study. An equivocal depression in the food consumption was recorded for some animals treated at 400 mg/kg bw/day. No significant dose-related changes occurred in the haematology parameters examined. The activity of cholinesterase in erythrocytes and plasma was depressed in blood samples taken pre-terminally from animals treated at 400 mg/kg bw/day, but no significant effect on the activity of cholinesterase in the brain could be determined. No significant effect on organ weights was seen, and there were no gross or histological changes of any type or incidence to suggest any systemic toxicity of the test substance.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.